Clinical Trials Logo

Clinical Trial Summary

It's a phase 2, single arm study of gemcitabine an docetaxel combination in patients with carcinoma of unknown primary.


Clinical Trial Description

n/a


Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT02590055
Study type Interventional
Source Samsung Medical Center
Contact Yoon Jung Ahn
Email younjeong.ahn@samsung.com
Status Recruiting
Phase Phase 2
Start date October 2015
Completion date September 2019

See also
  Status Clinical Trial Phase
Completed NCT00004005 - Irinotecan Followed By Fluorouracil and Leucovorin in Treating Patients With Stage III or Stage IV Colorectal Carcinoma (Cancer), Other Refractory Carcinoma, or Metastatic Adenoma (Cancer) of Unknown Primary Origin Phase 2
Completed NCT00003943 - Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Cancer. Phase 2
Completed NCT00002507 - Radiation Therapy and Chemotherapy in Treating Patients With Head and Neck Cancer Phase 3
Recruiting NCT03740503 - Genomic Investigation of Unusual Responders
Terminated NCT00148135 - Combination of Carboplatin, Gemcitabine, and Capecitabine in Patients With Carcinoma of Unknown Primary Site Phase 2
Completed NCT00003582 - Radiation Therapy, Combination Chemotherapy, and Amifostine in Treating Patients With Head and Neck Cancer Phase 1/Phase 2
Completed NCT00014456 - Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors Phase 1
Not yet recruiting NCT04985357 - Defining the Clinical Potential of Mass Response as a Biomarker for Patient Tumor Sensitivity to Drugs
Completed NCT00357630 - Gemcitabine in Treating Patients With Metastatic Cancer of Unknown Primary Phase 2
Active, not recruiting NCT01366144 - Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction Phase 1
Completed NCT00004922 - Irinotecan in Treating Patients With Advanced Neuroendocrine Tumors Phase 2
Recruiting NCT05887492 - Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors Phase 1/Phase 2
Withdrawn NCT00119314 - Gemcitabine, Docetaxel, and Capecitabine in Treating Patients With Cancer of Unknown Primary Origin Phase 2
Completed NCT00047125 - Radiation Therapy in Treating Patients With Metastases to the Lymph Nodes in the Neck From an Unknown Primary Tumor Phase 3
Completed NCT00003657 - High-dose ICE With Amifostine Phase 2
Recruiting NCT05461430 - Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
Recruiting NCT02764216 - Elective Mucosal Irradiation in Head-and-Neck Cancer of Unknown Primary Phase 2
Completed NCT00873119 - Belinostat, Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Cancer of Unknown Primary Phase 2
Completed NCT00388024 - PET Scans and CT Scans in Patients With Locally Advanced Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy N/A
Completed NCT00066781 - Gemcitabine and Irinotecan in Treating Patients With Cancer of Unknown Primary Phase 2